In This Issue of JAMA

February 14, 2017 Volume 317. Number 6 Pages 547-656

Research

Scalp Cooling Device for Chemotherapy-Induced Alopecia

Chemotherapy can induce alopecia. Nangia and colleagues report the results of a randomized clinical trial of 182 women with breast cancer undergoing chemotherapy, in which patients who used a scalp cooling device were less likely to have hair loss than patients who did not use the device. In an Editorial on this trial and a prospective cohort study on the same topic in this issue, Hershman discusses the distress of chemotherapy-induced alopecia and the costs of providing cooling devices to patients.

Editorial 587 Related Article 606 JAMA Patient Page 656

Author Audio Interview Jama.com CME Jamanetworkcme.com

Scalp Cooling for Chemotherapy-Related Alopecia



Alopecia is one of the most common and emotionally distressing adverse effects of chemotherapy. In a prospective cohort study by Rugo and colleagues of 122 patients receiving chemotherapy for breast cancer at 5 US medical centers, the use of scalp cooling (vs no scalp cooling) was associated with less hair loss at 4 weeks

after the last dose of chemotherapy. In an Editorial on this study and a clinical trial on the same topic in this issue, Hershman reports that many patients decline chemotherapy because of concerns about adverse effects such as alopecia.

Editorial 587 Related Article 596 JAMA Patient Page 656

Author Audio Interview jama.com

Sublingual Immunotherapy for Seasonal Allergic Rhinitis

Three years of continuous treatment with sublingual immunotherapy has been shown to improve symptoms of seasonal allergic rhinitis for at least 2 years following discontinuation of treatment. To determine whether a shorter course of immunotherapy could have similar benefits while reducing costs, patient inconvenience, and adverse events, Scadding and colleagues conducted a randomized clinical trial in 106 patients with moderateto-severe seasonal allergic rhinitis and found that 2 years of sublingual immunotherapy was not significantly different from placebo in improving the nasal response to allergen challenge at 3-year follow-up. In an Editorial, Cox discusses the costs and benefits of allergen-specific immunotherapy.

Editorial 591

™ CME jamanetworkcme.com



Joseph Mango, UCLA Center for Health Services and Society

Humanities

The Arts and Medicine 568 The One With Friends. A TV Show Within a Play

Poetry and Medicine 649 Internal Rhythm **ENorbie**

JAMA Revisited 650 Philology and Pathology

Opinion

Viewpoint

579 Hypertension in 2017— What is the Right Target? AV Chobanian

581 New "21st Century Cures" Legislation: Speed and Ease vs Science AS Kesselheim and J Avorn

583 Language for Actionable Recommendations in Clinical Guidelines: Avoiding Hedging and Equivocation RS Klasco and LH Glinert

A Piece of My Mind

585 Should the Definition of Health Include a Measure of Tolerance? RH Brook

606

615

587 Scalp Cooling to Prevent Chemotherapy-Induced Alopecia: The Time Has Come **DL** Hershman

589 When Will Mondelian Randomization Become Relevant for Clinical Practice and Public Health? G Davey Smith, L Paternoster, and C Relton.

591 Sublingual Immunotherapy for Allergic Rhinitis: Is 2-Year Treatment Sufficient for Long-term Benefit? LS Cox

594 Clinical Practice Guidelines: Expanded Use and Misuse SGreenfield

LETTERS

Research Letter

642 Two-Year Follow-up of a Randomized Clinical Trial of Mindfulness-Based Stress Reduction vs Cognitive Behavioral Therapy or Usual Care for Chronic Low Back Pain DC Cherkin and Coauthors

Comment & Response

644 Therapeutic Hypothermia After Cardiac Arrest

645 Birth Center Model of Care

646 Oxygen Supplementation Among Patients in the Intensive Care Unit

648 Correction

Editor in Chief Howard Bauchner, MD **133** YEARS OF CONTINUOUS PUBLICATION

In This Issue of JAMA

February 14, 2017 Volume 317, Number 6 Pages 547-656

Research (continued)

Waist-to-Hip Ratio and Coronary Heart Disease

626

The reported association of abdominal adiposity with type 2 diabetes and coronary heart disease may have been confounded by unmeasured lifestyle factors. To evaluate the genetic determinants of this association, Emdin and colleagues compiled data on 111986 individuals from the UK Biobank and found that a genetic predisposition to higher waist-to-hip ratio adjusted for body mass index was associated with increased risk of type 2 diabetes and coronary heart disease. In an Editorial, Davey Smith and colleagues explain how mendelian randomization can enhance the clinical and public health relevance of observational studies.

Editorial 589

ECME jamanetworkcme.com

Clinical Review & Education

Metabolic Surgery for Type 2 Diabetes

635

Bariatric interventions can alter glucose homeostasis by their effects on the gut microbiome, hormones, and bile acid metabolism; consequently, they may be thought of as metabolic surgeries when the goal is to improve metabolic health rather than weight alone. This JAMA Clinical Guidelines Synopsis article by Brito and colleagues discusses the clinical implications of a joint statement by international diabetes organizations recommending metabolic surgery as a treatment option for selected patients with type 2 diabetes and obesity. In an Editorial, Greenfield discusses the expanded use and misuse of Clinical Practice Guidelines.

Editorial 594 Related Article 571

Fever and a Pustular Rash

637



This JAMA Clinical Challenge article by Yek and colleagues describes a man in his 40s with fever, a rash, and progressing acneiform papules and pustules that began 3 days after taking an ibuprofen pill for a mild headache. A punch biopsy of the skin showed subcorneal pustules containing neutrophils and eosinophils, with epidermal spongiosis. What would you do next?

Quiz Jama.com

From The Medical Letter: Sofosbuvir/Velpatasvir for Hepatitis C 63

This *Medical Letter on Drugs and Therapeutics* article discusses the benefits and risks of Epclusa—an oral combination of sofosbuvir and velpatasvir—the first medication to be approved for treatment of all 6 major hepatitis C virus genotypes.

M Online @ jama.com



Editor's Audio Summary

Edward H. Livingston, MD, summarizes and comments on this week's issue.

Just Published

Read the latest JAMA content published online first at jamanetwork.com/journals/jama/newonline.

Author Interview



AUDIO JAMA Senior Editor Mary McDermott, MD, interviews authors Julie Nangia, MD, and Hope S. Rugo, MD, on the use of a scalp cooling

system to alleviate hair loss in women receiving chemotherapy for breast cancer.

The s

JAMA Patient Page

656 Chemotherapy and Hair Loss

NEWS & ANALYSIS

Medical News & Perspectives

571 Unveiling the "Magic" of Diabetes Remission After Weight-Loss Surgery

The JAMA Forum

574 Mitochondrial Replacement Therapy: Unmade in the USA

576 Capitol Health Call

Concerns Over Newborn Screening

Uncertain Future for Preexisting Conditions.

Cassidy Rolls Up His Sleeves

577 News From the CDC

Help Patients Have Smoke-Free Life Football's Toll on Student Athletes

Departments

559 Staff Listing

641 CME Questions

651 Classified Advertising

654 Journal Advertiser Index

655 Contact Information

Instructions for Authors

Jama.com/public /instructionsforauthors.aspx